






1 **Supplemental Table. Sources of Primary Antibodies Used in Study**

<b>Antibody (Flow cytometry)</b>	<b>Clone number</b>	<b>Conjugated</b>	<b>Brand</b>
LIVE/DEAD Fixable Dead Cell Stain Kit	-N/A	Near-IR	Molecular Probes
anti-mouse B220	RA3-6B2	Pacific Blue	Invitrogen
anti-mouse CD11b	M1/70	PE-Cy7	BD Pharmingen
anti-mouse CD11c	HL3	Alexa Fluor 700	BD Pharmingen
anti-mouse CD16/CD32	2.4G2	-	BD Pharmingen
anti-mouse CD19	1D3	PerCP-Cy5.5, APC	BD Pharmingen
anti-mouse CD19	6D5	Brilliant Violet 605	BioLegend
anti-mouse CD1d	1B1	PE	eBioscience
anti-mouse CD21	7G6	Brilliant Violet 650	BD Pharmingen
anti-mouse CD210 (IL-10R)	1B1.3a	functional grade	BD Pharmingen
anti-mouse CD23	B3B4	PE	eBioscience
anti-mouse CD24	M1/69	APC	BD Pharmingen
anti-mouse CD25	PC61.5	PE	eBioscience
anti-mouse CD282 (TLR2)	QA16A01	functional grade	BioLegend
anti-mouse CD3	145-2C11	eFluor 450, PE-Cy5	eBioscience
anti-mouse CD3	17A2	functional grade	R&D systems
anti-mouse CD4	GK1.5	PE-Cy7	BD Pharmingen
anti-mouse CD4	RM4-5	APC	BioLegend
anti-mouse CD45	30-F11	Pacific Orange	Invitrogen
anti-mouse CD49b	DX5	PE-Cy7	eBioscience
anti-mouse CD5	53-7.3	PE-Cy5	BD Pharmingen
anti-mouse CD8a	53-6.7	PE-Cy7	eBioscience
anti-mouse F4/80	BM8	Alexa Fluor 647	Invitrogen
anti-mouse F4/80	BM8	PE	eBioscience
anti-mouse Foxp3	FJK-16s	eFluor 660	eBioscience
anti-mouse IL-10	JES5-16E3	APC	BD Pharmingen
anti-mouse IgD	11-26c.2a	APC	BD Pharmingen
anti-mouse IgM	II/41	PE-Cy7	eBioscience
anti-mouse MHC-II	M5/114.15.2	Brilliant Violet 650	BioLegend
anti-mouse RORgt	Q31-378	Alexa Fluor 647	BD Pharmingen
hamster IgG1 $\lambda$	G235-2356	PerCP-Cy5.5	BD Pharmingen
hamster IgG1 $\lambda$	A19-3	APC	BD Pharmingen


mouse IgG1 $\kappa$	MOPC-21	functional grade	BioLegend
mouse IgG2a $\kappa$	G155-178	Alexa Fluor 647	BD Pharmingen
rat IgG1 $\kappa$	eBRG1	PE	eBioscience
rat IgG1 $\kappa$	R3-34	functional grade	BD Pharmingen
rat IgG1 $\lambda$	G0114F7	PE	BioLegend
rat IgG2a $\kappa$	R35-95	PE	BD Pharmingen
rat IgG2a $\kappa$	RTK2758	Brilliant Violet 605	BioLegend
rat IgG2a $\kappa$	eBR2a	eFluor 660	eBioscience
rat IgG2b $\kappa$	A95-1	PE-Cy7, PE-Cy5, APC	BD Pharmingen
rat IgG2b $\kappa$	R35-38	Brilliant Violet 650	BD Pharmingen
<b>Antibodies ( Immunohistochemistry)</b>			
<b>Clone number</b>	<b>Catalog number</b>	<b>Brand</b>	
anti-GFP	-	A-11122	Invitrogen
anti-mouse B220	RA3-6B2	550286	BD Pharmingen
anti-mouse CD3	145-2C11	550275	BD Pharmingen
anti-rabbit IgG (unconjugated)	-	31210	Invitrogen
<b>Antibodies (Western blots)</b>			
<b>Clone number</b>	<b>Catalog number</b>	<b>Brand</b>	
anti-p-STAT3 (Y705)	D3A7	9131	Cell Signaling Technology
anti-STAT3	79D7	4904	Cell Signaling Technology
anti-p-Akt (Ser473)	D9E	4060	Cell Signaling Technology
anti-Akt	C67E7	4691	Cell Signaling Technology
anti-pERK1/2 (T202/Y204)	D13.14.4E	4370	Cell Signaling Technology
anti-ERK1/2	C-16	sc-093	Santa Cruz Biotechnology
anti-pp38 (T180/Y182)	28B10	9216	Cell Signaling Technology
anti-p38	-	9212	Cell Signaling Technology
anti-p-p85 (Y458/Y199)	-	4228	Cell Signaling Technology
anti-p85	19H8	4257	Cell Signaling Technology
anti-p-PDK1 (Ser241)	C49H2	3438	Cell Signaling Technology
anti-PDK1	-	3062	Cell Signaling Technology
anti-p-GSK3 $\beta$ (Ser9)	D85E12	5558	Cell Signaling Technology
anti-GSK3 $\alpha/\beta$	D75D3	5676	Cell Signaling Technology
anti-actin	C4	Sc-47778	Santa Cruz Biotechnology

3 **Supplemental Figures**




4 **Supplemental Figure 1. GFP<sup>+</sup> B cells exhibit higher *Il10* mRNA expression and produce more**  
5 **IL-10 protein than GFP<sup>neg</sup> B cells.** Splenic B cells from specific pathogen-free (SPF) *Il10*<sup>+EGFP</sup>  
6 reporter mice were cultured with 1nM CpG-DNA for 48 hours and separated into GFP<sup>+</sup> (96.2% pure) and  
7 GFP<sup>neg</sup> (GFP<sup>-</sup>) (98.7% pure) B cells by flow cytometry sorting. **(A)** mRNA expression in sorted GFP<sup>+</sup>  
8 and GFP<sup>-</sup> B cells were analyzed by real time PCR. Gene fold induction of GFP<sup>+</sup> over GFP<sup>-</sup> cells are  
9 shown. **(B)** Sorted B cells were further cultured without stimulation for 24 hours and supernatant level  
10 of IL-10 was measured by ELISA. N=4-5. Data are presented as median, Mann-Whitney U test. **(C)**  
11 Splenic B cells from SPF-raised *Il10*<sup>+EGFP</sup> reporter mice or WT (GFP<sup>-</sup>) mice were cultured *in vitro* with  
12 1nM CpG for 24 hours, intracellularly stained with anti-IL-10 antibody or isotype control antibody  
13 followed by CD19, B220, CD45 and LIVE/DEAD™ Fixable Dead Cell Stain Kit cell surface staining, and  
14 analyzed with flow cytometry as described in Methods, Flow cytometry section. As a negative control  
15 for GFP, WT cells were stained with the same antibodies except GFP/FITC. Representative dot plots in  
16 B cell gate (live CD45<sup>+</sup>CD19<sup>+</sup>B220<sup>+</sup>) are shown. **(D)** The gating strategy targeting GFP<sup>+</sup> cells is  
17 demonstrated. When *Il10*<sup>+EGFP</sup> reporter cells were used, SPF-raised C57BL/6 WT (GFP<sup>-</sup>) cells were  
18 utilized. WT cells were stained with the same antibodies as target samples to determine a basal  
19 intensity level of GFP and set a GFP gate, as a Fluorescence minus one (FMO) control.  
20 Representative dot plots for GFP<sup>+</sup> CD45<sup>+</sup> cells (LIVE/DEAD™ Fixable Dead Cell Stain Kit (APC-Cy7)<sup>neg</sup>  
21 CD45 (Pacific Orange)<sup>+</sup>GFP<sup>+</sup>) related to **Figure 1A, middle** are shown for demonstration.

22 N=3-5/group. Each sample was pooled from 2-3 mice. Data are presented as median, \* $p < 0.05$ ,  
23 Kruskal-Wallis test with Dunn's posttest. **(E and F)** Association between **(E)** GFP<sup>+</sup> cells and IL-10  
24 protein concentrations and **(F)** GFP<sup>+</sup> cells and *Il10* mRNA expression *in vivo* are analyzed by using the  
25 raw data in **Figure 1A**. Correlation between GFP<sup>+</sup> cells and IL-10 protein or mRNA levels was  
26 determined by Pearson's Correlation Coefficient.



27 **Supplemental Figure 2. SPF bacteria were stably colonized in ex-GF mice.** Feces collected from  
 28 SPF-born *Il10<sup>+/EGFP</sup>* reporter (Vert-X) mice were inoculated into 8-12-week-old germ-free (GF) Vert-X  
 29 mice. After inoculation, fecal samples were collected weekly and the bacterial populations were  
 30 evaluated by 16S rRNA gene sequencing by the Illumina MiSeq platform and analyzed by QIIME. The  
 31 relative abundance ratios of fecal bacterial taxa sequentially over 6 weeks are shown with baseline  
 32 (original) values from the SPF mouse feces used to colonize the GF mouse. N=3/group.




33

34 **Supplemental Figure 3. Colonization of resident bacteria induces variable subsets of CD4<sup>+</sup> T**

35 **cells in the colon LP, but not MLN or spleen and stimulates colonic immune gene expression.**

36 **(A)** IL-10-producing GFP<sup>+</sup> colonic Foxp3<sup>neg</sup>CD4<sup>+</sup> T cells (Tr1) cells, **(B)** GFP<sup>+</sup>CD25<sup>+</sup>CD4<sup>+</sup> T cells  
 37 (CD25<sup>+</sup>CD4<sup>+</sup>CD3<sup>+</sup>), GFP<sup>+</sup>CD8<sup>+</sup> T cells (CD8<sup>+</sup>CD3<sup>+</sup>), GFP<sup>+</sup> macrophages (F4/80<sup>+</sup>CD11b<sup>+</sup>), GFP<sup>+</sup> dendritic  
 38 cells (CD11c<sup>+</sup>CD11b<sup>+</sup>), and **(C)** GFP<sup>+</sup> or GFP<sup>-</sup> Foxp3<sup>+</sup>CD4<sup>+</sup> T cells in the colonic lamina propria (LP) were  
 39 assessed by flow cytometry from GF, SPF-raised (SPF) or conventionalized ex-GF [3 days (D3) and 7  
 40 days (D7) after colonization with SPF feces] *Il10*<sup>+EGFP</sup> reporter mice. All cells were stained with Foxp3


41 eFlour660 and also stained with CD45 and LIVE/DEAD™ Fixable Dead Cell Stain Kit. Colon LP cells  
42 from WT mice stained with the same antibodies as sample cells were used as negative controls for GFP.  
43 **(D)** Colonization of resident bacteria does not induce GFP<sup>+</sup> cells in the MLN or spleen. GFP<sup>+</sup> spleen  
44 and MLN cells from the three groups of mice described above were analyzed by flow cytometry as  
45 shown above and live CD45<sup>+</sup> cells were analyzed. MLN cells or splenocytes from WT mice were used  
46 as negative controls for GFP. **(E)** Stimulation of immune regulatory gene expression in colonic mucosa  
47 by bacterial colonization. Kinetic expression of selected immune-related genes in the distal colons  
48 from the three groups of mice described above was determined by real-time PCR. Each gene was  
49 normalized by *Actb*. N=5-8/group, combined from 2-3 independent experiments. All data are  
50 presented as median except **Figure C** (Mean ± standard error), \**p*<0.05, \*\**p*<0.01, \*\*\**p*<0.001, *N.S.*: not  
51 significant, Kruskal-Wallis test with Dunn's posttest.



52

53 **Supplemental Figure 4. Phenotypic characteristics of colonic GFP<sup>+</sup> B cells.** Colon LP cells were  
 54 freshly isolated from SPF-raised *Il10<sup>+</sup>/EGFP* reporter mice. GFP<sup>+</sup> or GFP<sup>-</sup> live B cell populations (B220  
 55 (Pacific blue)<sup>+</sup>CD19 (BV605)<sup>+</sup>CD45 (Pacific orange)<sup>+</sup>LIVE/DEAD<sup>TM</sup> Fixable Dead Cell Stain kit  
 56 (Near-IR)<sup>neg</sup>) were further analyzed by flow cytometry with the following phenotypic markers: IgM  
 57 (PE-Cy7), IgD (APC), CD5 (PE-Cy5), CD1d (PE), MHC-II (Qdot655), CD21 (Qdot655), CD23 (PE), and  
 58 CD24 (APC). As negative control for GFP (FMO control), colon LP cells from WT mice stained with the  
 59 same antibodies as sample cells were used for setting the GFP-gate and compensation.  
 60 Representative dot plots of GFP<sup>+</sup> and GFP<sup>-</sup> cells gated on B cells (CD19<sup>+</sup>B220<sup>+</sup>) are shown. N=4, each  
 61 sample was pooled from 3 mice. 2 independent experiments.

62



63

64 **Supplemental Figure 5. Chronic colonic inflammation increases the frequency of colonic**

65 **GFP<sup>+</sup>IL-10-producing T and B cells in the presence of resident bacteria.** Colonic LP cells were


66 isolated from SPF-raised *Il10<sup>+/EGFP</sup>* mice without (control) or following treatment with 3 cycles of 1.5%

67 dextran sulfate sodium (DSS) administration (DSSx3). **(A)** Total live CD45<sup>+</sup>GFP<sup>+</sup> cells in colon LP cells,

68 and **(B)** three subpopulations of lymphoid cells (CD25<sup>+</sup>CD4<sup>+</sup>CD3<sup>+</sup>, CD25<sup>+</sup>CD4<sup>+</sup>CD3<sup>+</sup> and CD8<sup>+</sup>CD3<sup>+</sup> T

69 cells and CD19<sup>+</sup>B220<sup>+</sup> B cells) were characterized by flow cytometry as described in the Methods. SPF

70 WT mice were used as a negative control for GFP. N=4-5/group, combined from 2 independent  
71 experiments. Data are presented as median, Mann-Whitney U test. **(C)** Representative dot blots for  
72 LP GFP<sup>+</sup>CD4<sup>+</sup> T cells (CD4<sup>+</sup>CD3<sup>+</sup>-gated) and GFP<sup>+</sup> B cells (CD19<sup>+</sup>B220<sup>+</sup>-gated) in SPF untreated  
73 (control) and with 3 cycles of DSS-treated (DSSx3) mice are shown. **(D)** The distribution of GFP<sup>+</sup> B  
74 cells and GFP<sup>+</sup> T cells in lymphoid aggregates and the LP of the distal colon from DSS-treated mice was  
75 analyzed by immunohistochemistry. GFP<sup>+</sup> cells are shown in green and B cells (B220<sup>+</sup>) and T cells  
76 (CD3<sup>+</sup>) are shown in red. Tissue sections were counterstained with DAPI. Bottom panel is a higher  
77 magnification image of the rectangular area indicated in the top panel.



78

79 **Supplemental Figure 6. CBL is unable to suppress colonic LP cell IL-12p40 production in the**  
 80 **absence of IL-10 or IL-10 signaling and bacterial products stimulate IL-10 secretion ex vivo. (A)**

81 Unfractionated colonic LP cells from GF or SPF-raised *Il10*<sup>-/-</sup> mice were cultured with 0-100ug/ml of cecal

82 bacterial lysate (CBL) from SPF WT mice for 2 days. **(B)** In parallel, unfractionated colonic LP cells



83 from SPF-raised WT mice were cultured with and without 100ug/ml CBL in the presence or absence of

84 10ug/ml anti-IL-10R antibodies for 2 days. IL-12p40 levels in culture supernatants were measured by

85 ELISA. Data are presented as median of 4-5 separate cell cultures with cells in each culture pooled

86 from 2-4 mice, \* $p < 0.05$ , N.S.: not significant, Kruskal-Wallis test with Dunn's posttest. **(C)** Bacterial

87 products stimulate IL-10 secretion in colonic cells, *ex vivo*. Unfractionated colonic LP cells from GF  
88 *Il10<sup>+EGFP</sup>* reporter mice were cultured without (-, media only) or with 200ng/ml LPS, 50ng/ml Pam3csk  
89 (Pam), 1nM CpG-DNA (CpG), 10µg/ml of lysates of *E. coli* LF82 (*Ec*), *Enterococcus faecalis* (*Ef*),  
90 *Ruminococcus gnavus* (*Rg*) or a mixture of 17 *Clostridia* strains (*Clo*) for 2 days. IL-10 levels in culture  
91 supernatants were measured by ELISA. Data are presented as the median of 4 separate cell cultures  
92 with cells in each culture pooled from 2-4 mice, \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , vs. non-stimulation,  
93 Kruskal-Wallis test with Dunn's posttest.




94

95 **Supplemental Figure 7. Colonic B cells suppress T cell proliferation and differentiation in the**  
 96 **presence of CBL stimulation.** CFSE-labeled colonic CD4<sup>+</sup> T cells ( $5 \times 10^5$ ) were cultured with or  
 97 without different numbers of colonic B cells ( $0$ ,  $2.5 \times 10^5$ ,  $5.0 \times 10^5$ ,  $1.0 \times 10^6$ ,  $2.5 \times 10^6$ ) from SPF mice on  
 98 CD3-coated plates for 24 hours in the presence or absence of CBL stimulation. T cell proliferation was  
 99 determined by the loss of intensity of CFSE staining in live CD45<sup>+</sup> CD4<sup>+</sup>CD3<sup>+</sup> T cells using flow cytometry.  
 100 **(A)** Representative histograms of T cell proliferation in CBL-treated co-cultures with the degree of  
 101 proliferation noted. **(B)** Quantified T cell proliferation. **(C)** Supernatant levels of IFN $\gamma$  and IL-17a  
 102 measured by ELISA. Data are presented as the median of 4-5 separate cell cultures with cells in each

103 culture pooled from 2-4 mice. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , Kruskal-Wallis test with Dunn's posttest.

104 *N.S.*: not significant.



105

106 **Supplemental Figure 8. Lack of TLR2/MyD88-signaling negates resident bacteria-stimulated**


107 **development of inducible, but not native, mucosal IL-10-producing GFP<sup>+</sup> B cells, but has no**

108 **effect on IL-12 production.** Unfractionated colon LP cells from 8-10-week old WT *Il10*<sup>+/EGFP</sup>,

109 *Tlr2*<sup>-/-</sup> *Il10*<sup>+/EGFP</sup>, *Tlr4*<sup>-/-</sup> *Il10*<sup>+/EGFP</sup> and *Myd88*<sup>-/-</sup> *Il10*<sup>+/EGFP</sup> mice were cultured with or without ex vivo CBL

110 (10µg/ml)-stimulation for 24 hours, then GFP<sup>+</sup> cell populations were analyzed by flow cytometry and

111 supernatant IL-10 and IL-12p40 measured by ELISA. **(A)** Representative dot plots for LP GFP<sup>+</sup> B cells  
112 (CD19<sup>+</sup>B220<sup>+</sup>). **(B)** CBL-stimulated IL-12p40 production is TLR-independent. IL-10 and IL-12p40  
113 production by colonic tissue explants, and ratios of IL-10/IL-12p40 are shown. Data are presented as  
114 median. N=7/group, combined from 2 independent experiments. \* $p < 0.05$ , Kruskal-Wallis test with  
115 Dunn's posttest.



116

117 **Supplemental Figure 9. B cells are the primary source of bacteria-stimulated**

118 **TLR2/MyD88-dependent IL-10-production in colon.** Freshly isolated unfractionated colonic LP cells


119 from *Myd88*<sup>-/-</sup>, *Tlr2*<sup>-/-</sup> and WT mice were magnetically separated into B cell and non-B cell populations.

120 B cells or non-B cells ( $5 \times 10^5$ ) were independently cultured with or without 10µg/ml CBL for 24 hours,

121 then supernatant levels of IL-10 were measured by ELISA. Data are presented as median of 4

122 separate cell cultures with cells in each culture pooled from 2-4 mice, \* $p < 0.05$ , \*\* $p < 0.01$ , Kruskal-Wallis

123 test with Dunn's posttest.



124

125 **Supplemental Figure 10. B cells ameliorate experimental T cell-mediated colitis in IL-10 and**

126 **TLR2/MyD88-dependent manners, *in vivo*.** Splenic B cells ( $1 \times 10^6$ ) from SPF-raised WT, *Il10*<sup>-/-</sup>,


127 *Myd88*<sup>-/-</sup>, *Tlr2*<sup>-/-</sup> and *Tlr4*<sup>-/-</sup> mice were co-transferred with WT naïve CD4<sup>+</sup> T cells ( $5 \times 10^5$ ) into SPF

128 *Rag2*<sup>-/-</sup>*Il10*<sup>-/-</sup> recipients. Six weeks after cell transfer, mice were evaluated for severity of colitis by


129 histology with hematoxylin and eosin staining. Representative photomicrographs of the cecum

130 associated with **Figure 7C** are shown. Magnification: 100x.

131



132 **Supplemental Figure 11. TLR2 signaling activates the PI3K/AKT/GSK3B pathway in**  
 133 **CBL-stimulated B cells.** (A) Splenic B cells from 8-10-week-old SPF WT, *Tlr2*<sup>-/-</sup> and *Tlr4*<sup>-/-</sup> mice were  
 134 cultured with or without 10µg/ml CBL. Cells were harvested 0 and 30 minutes after CBL stimulation  
 135 and phosphorylation of the indicated protein was analyzed by Western blots using antibody to signaling  
 136 pathway components. (B) Schematic pathways of TLR2-dependent activation of IL-10 signaling in  
 137 CBL-stimulated B cells. The molecules indicated in orange were assessed by Western blots in this  
 138 study.



139

140 **Supplemental Figure 12. The PI3K pathway is partially involved in induction of GFP<sup>+</sup> B cell by**

141 **CBL.** Splenic B cells (1x10<sup>6</sup>/well) from 8-10-week old SPF *I110<sup>+/EGFP</sup>* mice were cultured with 1uM

142 pan-PI3K inhibitors; Wortmannin or Ly294002, 1uM PI3Kp110δ-specific inhibitor; IC-87114, or DMSO

143 alone with stimulation of 10μg/ml CBL for 48hours. GFP<sup>+</sup> B cells (live CD45<sup>+</sup>CD19<sup>+</sup>B220<sup>+</sup>) were

144 analyzed with flow cytometry in reference to WT (GFP<sup>-</sup>) control cells stained with the same antibodies as

145 target samples. Representative flow cytometry plots related to **Figure 8D**

146 **Supplemental methods**

147 **Flow cytometric cell sorting**

148 Freshly isolated splenic B cells were cultured with 1nM CpG for 24 hours and then GFP<sup>+</sup> or  
149 GFP<sup>-</sup>CD19<sup>+</sup>B220<sup>+</sup> B cells were sorted by BD FACS Aria III (BD Biosciences, San Jose, CA). Purity:  
150 GFP<sup>+</sup>B cells 96.2%, GFP<sup>-</sup>B cells 98.7%. As a negative control for GFP, colon LP cells from WT mice  
151 stained with the same antibodies used to stain the sample cells that were used for setting the GFP-gate  
152 and compensation.

153

154 **Isolation of fecal microbial DNA and sequencing of 16S rRNA gene**

155 Bacterial DNA was extracted from fecal pellets with a phenol-chloroform DNA extraction  
156 method with physical agitation to rupture bacterial envelopes, as previously described (1). The  
157 resulting DNA was cleaned using a DNA clean-up kit (Qiagen DNeasy Blood & Tissue Kit. Valencia,  
158 CA). The bacterial composition of fecal samples was determined by amplification and sequencing of  
159 the V4 region of the 16S rRNA gene. The V4 region was amplified with two distinct polymerase chain  
160 reactions. The first reaction employed validated 16S rRNA V4 primers (forward 515 and reverse 806),  
161 using the KAPA2G Robust PCR kit. Thermocycling conditions for the first reaction were 95°C/3m; 10

162 cycles of 95°C/30s, 50°C/30s and 72°C/30s, respectively; and 72°C/5m. For the second reaction, 5 µL  
163 of cleaned product from the first reaction was amplified with the KAPA HiFi HotStart ReadyMix PCR kit  
164 (Roche Diagnostics, Indianapolis, IN) using Illumina MiSeq adapter primers with a 12-base Golay  
165 barcode appended to the reverse primer (2). Thermocycling conditions for the second reaction were  
166 95°C/3m; 22 cycles of 95°C/30s, 50°C/30s and 72°C/30s, respectively; and 72°C/5m. After each PCR  
167 step, the amplicons were purified with the HighPrep PCR Clean Up Kit (MagBio, Gaithersburg, MD).  
168 The final purified amplicons were quantified, equimolar pooled, and sequenced on a desktop Illumina  
169 MiSeq (2x250) at the High-Throughput Sequencing Facility at University of North Carolina at Chapel Hill.  
170 Sequence data analysis was performed with QIIME (3). OTUs were picked with a 97% similarity  
171 threshold and taxonomy was assigned using the Greengenes database.

172

### 173 Chronic DSS-induced colitis

174 Chronic intestinal inflammation was induced by repetitive administration of 1.5% w/v dextran  
175 sulfate sodium (DSS; ICN Biomedicals, Aurora, OH) drinking water solution in the SPF-raised *Il10<sup>+/EGFP</sup>*  
176 mice. The control group was given normal water lacking DSS. Each cycle consisted of 7 days with  
177 DSS solution followed by 14 days without DSS solution, which continued for 3 cycles.

178

179 T cell suppression assay

180 Colonic LP cells were freshly isolated as described in the Cell isolation section of Methods from  
181 SPF WT mice. CD4<sup>+</sup> T cells and B cells were independently further isolated by CD4 and CD19  
182 microbeads, respectively (Miltenyi Biotec, Auburn, CA). CD4<sup>+</sup> T cells were labeled with CFSE (Sigma,  
183 St. Louis, MO) as per the manufacturer's protocol. 5x10<sup>5</sup> CD4<sup>+</sup> T cells were cultured on 48-well plates  
184 coated with 10ug/ml anti-CD3 antibody (BD Biosciences, San Jose, CA), with 0-2.5 x 10<sup>6</sup> colonic LP B  
185 cells in the presence or absence of 10ug/ml of CBL for 72 hours. Cells were harvested and  
186 proliferation of T cells was assessed by flow cytometry. Supernatant levels of IL-17a and IFN $\gamma$  were  
187 measured by ELISA.

188

189 Western blots

190 Western blots were performed as described in the Western blots session of Method. Primary  
191 antibodies used in Supplemental Figure 11 were described in the Supplemental Table. All primary  
192 antibodies were used at 1:1,000.

193

194 **Supplemental references**

- 195 1. Carroll IM et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in  
196 diarrhea-predominant irritable bowel syndrome.. *Am. J. Physiol. Gastrointest. Liver Physiol.*  
197 2011;301(5):G799-807.
- 198 2. Werner JJ et al. Impact of training sets on classification of high-throughput bacterial 16s rRNA gene  
199 surveys.. *ISME J.* 2012;6(1):94–103.
- 200 3. Caporaso JG et al. QIIME allows analysis of high-throughput community sequencing data.. *Nat.*  
201 *Methods* 2010;7(5):335–6.